2016: Big Impact, New Targets and a Bright Future

One million four-hundred thousand more men are alive today than was projected when PCF was founded in 1993. That’s enough to fill 28 Yankee Stadiums.

And 99% of men diagnosed with the disease today can expect to survive past the all-important five-year mark.

Since its founding, PCF has been involved in nearly every major research breakthrough in the field. Prostate cancer deaths are down more than 50% since 1993.

More than ever, advances against one form of cancer may translate to treatments for other types, as we begin to understand cancer by its unique genetic fingerprint rather than by where it arises anatomically. A precision treatment that’s effective for certain types of prostate cancer, for instance, is equally effective against all colon cancers that are driven by the same pathway. The same is true of specific breast and lung cancer mutations as well as for some children’s cancers.

So while PCF is still laser-focused on prostate cancer, our work increasingly benefits all cancer patients.